NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer

CompletedPhase 2

Sponsor: Genzyme, a Sanofi Company

Conditions: Thyroid Cancer

Interventions: ZD6474 (vandetanib)

Countries: United States, France

The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinoma.

Eligibility overview

Sex: ALL

Age: 18 Years to 130 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Locally advanced or hereditary medullary thyroid cancer
* Signed informed consent
* One or more measurable lesions

Exclusion Criteria:

* Brain metastases or spinal cord compression
* Specific laboratory ranges
* Specific heart problems
* Prior chemotherapy and/or radiation therapy
* Participation in other trials within 30 days

Locations (6)

San Francisco, California, United States
New Haven, Connecticut, United States
New York, New York, United States
Durham, North Carolina, United States
Houston, Texas, United States
Villejuif, France